Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats

Journal of Clinical Investigation

Volumn 99, Issue 2, 1997, Pages 278-287

  Takemoto, Masao ^a   Egashira, Kensuke ^a   Usui, Makoto ^a   Numaguchi, Kohtaro ^a   Tomita, Hideharu ^a   Tsutsui, Hiroyuki ^a   Shimokawa, Hiroaki ^a   Sueishi, Katsuo ^b   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

angiotensin converting enzyme inhibitor; coronary circulation; left ventricular hypertrophy; nitric oxide; renin angiotensin system

Indexed keywords

ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE; DRINKING WATER; HYDRALAZINE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0031029539     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119156     Document Type: Article

References (47)

1. Moncada, S., and A. Higgs. 1993. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:2002-2012.
2. Dzau, V.J., and G.H. Gibbons. 1991. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension (Dallas). 18(Suppl. III): III115-III121.
3. Meyers, P.R., R.L. Minor, Jr., R. Guerra, Jr., J.N. Bates, and D.G. Harrison. 1990. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble to S-nitrocysteine than nitric oxide. Nature (Lond.). 345: 161-163.
4. Palmer, R.M., A.G. Ferrige, and S. Moncada. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond.). 327:524-526.
5. Garg, U.C., and A. Hassid. 1989. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin. Invest. 83:1774-1777.
6. McNamara, D.B., B. Bedi, H. Aurora, L. Tena, L.J. Ignarro, P.J. Kadowitz, and D.J. Akers. 1993. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem. Biophys. Res. Commun. 193:291-296.
7. Cooke, J.P., A.M. Singer, P. Tsao, P. Zera, R.A. Rowan, and M.E. Billingham. 1992. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 90:1168-1172.
8. Cayatte, A.J., J.J. Palacino, K. Horten, and R.A. Cohen. 1994. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thromb. 14:753-759.
9. Von der Leyen, H., G.H. Gibbons, R. Morishita, N.P. Lewis. L. Zhang, M. Nakajima, Y. Kaneda, J.P. Cooke, and V. Dzau. 1995. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA. 92:1137-1141.
10. Egashira, K., T. Inou, Y. Hirooka, A. Yamada, Y. Maruoka, H. Kai, M. Sugimachi, and A. Takeshita. 1993. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J. Clin. Invest. 91:29-37.
11. Zeiher, A.M., H. Drexler, B. Saubier, and H. Just. 1993. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J. Clin. Invest. 92:652-662.
12. Kuo, L., M.J. Davis, M.S. Cannon, and W.M. Chillian. 1992. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation. Restoration of endothelium-dependent responses by L-arginine. Circ. Res. 70:465-476.
13. Egashira, K., T. Inou, Y. Hirooka, A. Yamada, Y. Maruoka, H. Kai, M. Sugimachi, S. Suzuki, and A. Takeshita. 1993. Impaired coronary blood flow response to acetylcholine in patients with atherosclerosis and proximal atherosclerotic lesions. J. Clin. Invest. 91:29-39.
14. Ito, A., K. Egashira, T. Kadokami, Y. Fukumoto, T. Takayanagi, R. Nakaike, T. Kuga, K. Sueishi, H. Shimokawa, and A. Takeshita. 1995. Chronic inhibition of endothelium-derived nitric oxide synthesis causes coronary microvascular structural changes and hyperreactivity to serotonin in pigs. Circulation. 92:2636-2644.
15. Numaguchi, K., K. Egashira, M. Takemoto, T. Kadokami, H. Shimokawa, K. Sueishi, and A. Takeshita. 1995. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension (Dallas). 26(Part 1):957-962.
16. Kadokami, T., K. Egashira, K. Kuwata, Y. Fukumoto, T. Kozai, H. Yasutake, T. Kuga, H. Shimokawa, K. Sueishi, and A. Takeshita. 1996. Altered serotonin receptor subtypes contribute to microvascular hyperreactivity to serotonin in pigs with chronic inhibition of nitric oxide. Circulation. 94:182-189.
17. Arnal, J.F., L. Warin, and J.B. Michel. 1992. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J. Clin. Invest. 90:647-652.
18. Baylis, C., B. Mitruka, and A. Deng. 1992. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest. 90:278-281.
19. Bank, N., H.S. Aynedjian, and G.A. Khan. 1994. Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension (Dallas). 24:322-328.
20. Ribeiro, M.O., E. Antunes, G. Nicci, S.M. Lovisolo, and R. Zatz. 1992. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension (Dallas). 20:298-303.
21. Arnal, J.F., A.I.E. Amrani, G. Chatellier, J. Menard, and J.B. Michel. 1993. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension (Dallas). 22:380-387.
22. Schieffer, B., A. Wirger, M. Meybrunn, S. Seitz, J. Holtz, U.N. Riede, and H. Drexler. 1994. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 89:2273-2282.
23. Weinberg, E.O., F.J. Schoen, D. George, Y. Kagaya, P.S. Douglas, S.E. Litwin, H. Schunkert, C.R. Benedict, and B.H. Lorell. 1994. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 90:1410-1422.
24. Schunkert, H., V.J. Dzau, S.S. Tan, A.T. Hirsch, C.S. Apstein, and B.H. Lorell. 1990. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility and relaxation. J. Clin. Invest. 86:1913-1920.
25. Hirsch, A.T., H. Schunkert, M. Paul, and V.J. Dzau. 1991. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ. Res. 69:475-482.
26. Schunkert, H., J.R. Ingelfinger, A.T. Hirsch, S.S. Tang, S.E. Litwin, C.E. Talsness, and V.J. Dzau. 1992. Evidence for tissue-specific activation of renal angiotensin mRNA expression in chronic stable experimental heart failure. J. Clin. Invest. 90:1523-1529.
27. The SOLVD Investigators. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325:293-302.
28. Swedberg, K., P. Held, J. Kjekshus, K. Rasmossen, L. Ryden, and H. Wedel. 1992. CONSENSUS II: effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N. Engl. J. Med. 327: 678-684.
29. Loud, A.V., P. Anversa, F. Giacomelli, and J. Wiener. 1978. Absolute morphometric study of myocardial hypertrophy in experimental hypertension. I. Determination of myocyte size. Lab. Invest. 38:586-596.
30. Anversa, P., A.V. Loud, F. Giacomelli, and J. Wiener. 1978. Absolute morphometric study of myocardial hypertrophy in experimental hypertension. II. Ultrastructure of myocytes and interstitium. Lab. Invest. 38:597-609.
31. Cheung, H.S., and D.W. Cushman, 1973. Inhibition of homogenous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca. Biochem. Biophys. Acta. 293:451-463.
32. Hayashi, K., K. Nunami, J. Kato, N. Yoneda, M. Kubo, T. Ochiai, and R. Ishida. 1989. Studies of angiotensin-converting enzyme inhibitors. Synthesis and angiotensin-converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives. J. Med. Chem. 32:289-297.
33. Kourembanas, S., L.P. McQuillan, G.K. Leung, and D.V. Faller. 1993. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J. Clin. Invest 92:99-104.
34. Itoh, H., M. Mukoyama, R.E. Pratt, G.H. Gibbons, and V.J. Dzau. 1993. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J. Clin. Invest. 91:2268-2274.
35. Naftilan, A.J., R.E. Pratt, and V.J. Dzau. 1989. Induction of plateletderived growth factor A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J. Clin. Invest. 83:1419-1424.
36. Gibbons, G.H., R.E. Pratt, and V.J. Dzau. 1992. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J. Clin. Invest. 90: 456-461.
37. Sigusch, H.H., S.E. Campbell, and K.T. Weber. 1996. Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. Cardiovasc. Res. 31:546-554.
38. Hou, J., H. Kato, R.A. Cohen, A.V. Chobanian, and P. Brecher. 1995. Angiotensin II-induced cardiac fibrosis in rats is increased by chronic inhibition of nitric oxide synthase. J. Clin. Invest. 96:2469-2477.
39. Sadoshima, J., Y. Xu, H.S. Slayter, and S. Izumo. 1993. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 75:977-984.
40. Michel, J.B., Y. Xu, S. Blot, M. Philippe, and G. Chatellier. 1996. Improved survival in rats administered NG-nitro-L-arginine methyl ester due to converting enzyme inhibitor. J. Cariovasc. Pharmacol. 28:142-148.
41. Farhy, R.D., O.A. Carretero, K.L. Ho, and A.G. Scicli. 1993. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointimal proliferation. Circ. Res. 72:1202-1210.
42. deBlois, D., D.M. Lombardi, M.A. Garvin, and S.M. Schwartz. 1992. Inhibition by ramipril of intimai hyperplasia in the denuded rat carotid is reversed by HOE140, a kinin B2 receptor antagonist. Circulation. 86:I-226 (Abstr.).
43. Egashira, K., T. Inou, Y. Hirooka, A. Yamada, Y. Urabe, and A. Takeshita. 1993. Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. N. Engl. J. Med. 328:1659-1664.
44. Egashira, K., Y. Hirooka, T. Kuga, M. Mohri, and A. Takeshita. 1996. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation. 94:130-134.
45. Maseri, A., F. Crea, and J.C. Kaski. 1991. Mechanisms of angina pectoris in syndrome X. J. Am. Coll. Cardiol. 17:499-506.
46. Mosseri, M., R. Yarom, M.S. Gostman, and Y. Hasin. 1986. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation. 74:964-972.
47. Kaski, J.C., G. Rosano, S. Gavrielides, and L. Chen. 1994. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J. Am. Coll. Cardiol. 23: 652-657.